白消安、美法仑与卡非佐米大剂量化疗联合自体造血干细胞移植治疗多发性骨髓瘤
这项I/II期试验在初诊及复发难治多发性骨髓瘤患者中,于白消安联合美法仑(BuMel)方案前后加入卡非佐米(BuMelCar),主要终点为安全性与耐受性。19例患者中卡非佐米最大耐受剂量为36 mg/m2,2年无进展生存率全队列89%、最大耐受剂量队列100%,80%患者达微小残留病阴性。
要点
- 卡非佐米联合白消安、美法仑方案的最大耐受剂量为36 mg/m2。
- 3级毒性包括发热性中性粒细胞减少79%、黏膜炎21%、腹泻16%。
- 全队列2年无进展生存率89%,最大耐受剂量队列100%。
核心结论
- 卡非佐米联合白消安、美法仑(BuMelCar)方案在初诊及复发难治多发性骨髓瘤患者中可行,计划进一步研究该方案。
研究设计与样本
- I/II期试验,纳入初诊多发性骨髓瘤、复发/难治多发性骨髓瘤及既往自体造血干细胞移植失败的患者,共19例,主要终点为安全性与耐受性。
主要发现
- 73%患者为高危(R-ISS III期、不良遗传学或既往自体造血干细胞移植后复发)。
- 卡非佐米最大耐受剂量为36 mg/m2。
- 3级毒性:发热性中性粒细胞减少79%、黏膜炎21%、腹泻16%。
- 全队列2年无进展生存率89%,最大耐受剂量队列100%。
- 80%的全部患者和82%的最大耐受剂量队列患者达到微小残留病阴性。
关键数值与推荐
- 卡非佐米最大耐受剂量为36 mg/m2。
- 全队列2年无进展生存率89%,最大耐受剂量队列100%。
- 微小残留病阴性率:全部患者80%,最大耐受剂量队列82%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard of care for fit, newly diagnosed multiple myeloma patients includes induction therapy followed by consolidative high-dose chemotherapy with melphalan and autologous stem cell transplant (AHSCT). Intensified preparative regimens, such as busulfan and melphalan (BuMel), have shown promise to lengthen progression-free survival (PFS). We previously reported that the addition of bortezomib to BuMel improved PFS compared to melphalan alone in CIBMTR-matched controls. We now integrate the second-generation protease inhibitor, carfilzomib, before and after BuMel (BuMelCar) in a phase I/II trial with carfilzomib. Patients with NDMM, relapsed/refractory MM (RRMM) and those failing prior AHSCT were eligible. Primary end-points were safety and tolerability. Secondary end-points included minimal residual disease negativity rates, PFS and OS. The study enrolled 19 patients. 73% were high risk either due to R-ISS III status, adverse genetics or relapsed after prior AHSCT. The maximum tolerated dose (MTD) of carfilzomib was determined to be 36 mg/m2. Noted grade 3 toxicities were febrile neutropenia (79%), mucositis (21%) and diarrhoea (16%). The 2-year PFS for the whole cohort and MTD was 89% and 100% respectively. 80% of all patients and 82% of patients in the MTD cohort achieved MRD negativity. Further studies regarding this regimen are planned.
引用
- Hagen P, Norton J, Tsai S, et al. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma. Br J Haematol. 2024. PMID: 38176404. doi:10.1111/bjh.19281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。